Structured, multimodal medical programs designed to address the biological processes that drive aging \u2014 guided at every step by laboratory data specific to the individual patient.
Longevity Protocols: Individualized, Biomarker-Guided Programs for Healthy Aging
Structured, multimodal medical programs designed to address the biological processes that drive aging \u2014 guided at every step by laboratory data specific to the individual patient.
About Longevity Protocols
A longevity protocol is a structured, multimodal medical program designed to address the biological processes that drive aging — not just manage the diseases that result from them. The principle behind a longevity protocol is straightforward: aging affects multiple biological systems simultaneously, and a program that targets only one of these systems will produce limited results. A properly designed protocol addresses the interconnected hallmarks of aging in a coordinated way, guided at every step by laboratory data specific to the individual patient.
At Advanced Vitality Group, no two longevity protocols are the same. A patient with declining testosterone, elevated fasting insulin, and a high hs-CRP has a very different biological profile than a patient with normal hormones but low NAD+, elevated GDF-15, and signs of accelerated cellular senescence. Both need longevity medicine — but they need different things from it. This is why we invest heavily in the baseline assessment before designing any protocol.
Why Multimodal Protocols Outperform Single Interventions
The hallmarks of aging, as defined by Lopez-Otin and colleagues in their landmark 2023 Cell paper, are not independent events — they are interconnected. Mitochondrial dysfunction drives inflammatory signaling. Chronic inflammation accelerates cellular senescence. Cellular senescence amplifies the inflammatory environment. Hormone decline compounds metabolic deterioration. NAD+ depletion impairs DNA repair, which in turn accelerates genomic instability.
Targeting only one of these nodes may produce modest improvements, but it leaves the underlying network of aging pathways largely intact. A multimodal protocol that addresses hormonal balance, cellular energy, inflammation, and tissue repair simultaneously produces synergistic effects — and this is what the clinical evidence for comprehensive longevity medicine consistently demonstrates.
The Structure of a Longevity Protocol
Comprehensive Baseline Assessment
The starting point for every longevity protocol is a thorough laboratory panel and clinical evaluation. This typically includes:
- Hormonal panel: Total and free testosterone, estradiol, SHBG, LH, FSH, DHEA-S, IGF-1, TSH, Free T3, Free T4
- Metabolic panel: Fasting insulin, fasting glucose, HbA1c, HOMA-IR, full lipid panel with ApoB, liver and kidney function
- Inflammatory markers: hs-CRP, IL-6, TNF-alpha, ferritin
- Cellular aging markers: NAD+ (whole blood), GDF-15, optionally telomere length
- Nutritional status: Vitamin D (25-OH), B12, folate, magnesium, zinc, omega-3 index
- Cardiovascular risk: Homocysteine, Lp(a), advanced lipid particle analysis where indicated
Protocol Design and Initiation
Based on the baseline findings, we design an individualized protocol organized around evidence-based intervention tiers. The foundation — and the most evidence-rich component — is lifestyle medicine: a structured exercise prescription combining aerobic and resistance training, dietary optimization consistent with a Mediterranean or whole-food pattern, and sleep hygiene. These are not optional additions; they are the most powerful tools available for mitochondrial biogenesis, autophagy activation, inflammatory reduction, and metabolic health.
Physician-supervised interventions are added based on laboratory findings. For patients with documented hormone deficiency, optimization follows Endocrine Society and American Urological Association guidelines. For patients with evidence of NAD+ insufficiency or mitochondrial dysfunction, NAD+ precursor supplementation (NMN or NR) is initiated with clear communication about the current Phase 1/2 evidence base. For patients with significantly elevated inflammatory markers or senescence burden, targeted anti-inflammatory or senolytic protocols are considered on an individualized basis.
Monitoring and Optimization
Protocols are not static. Biomarkers are retested at regular intervals — typically at weeks 8–12 and then every three to six months — and the protocol is adjusted based on response. This ongoing monitoring serves two purposes: it confirms that interventions are producing the intended biological changes, and it catches any emerging issues before they become clinical problems. Longevity medicine practiced without monitoring is not longevity medicine — it is guesswork.
Evidence-Based Components and Their Clinical Support
| Component | Evidence Level | Key Clinical Source |
|---|---|---|
| Exercise prescription (aerobic + resistance) | Grade A — systematic reviews and meta-analyses | Lee DH et al., JAMA Internal Medicine, 2022 |
| Testosterone optimization (hypogonadal men) | Grade A — RCTs and AUA/Endocrine Society guidelines | Snyder PJ et al., NEJM, 2016; AUA Guideline 2022 |
| Mediterranean dietary pattern | Grade A — meta-analyses of RCTs | Mentella MC et al., Nutrients, 2019 |
| NAD+ precursors (NMN/NR) | Grade B — Phase 1/2 RCTs; Phase 3 ongoing | Yoshino M et al., Science, 2021; Martens CR et al., 2018 |
| Omega-3 fatty acids (EPA + DHA) | Grade A for inflammation; Grade A for CVD (REDUCE-IT) | Bhatt DL et al., NEJM, 2019 |
| Senolytic therapy (D+Q) | Grade B — Phase 2 RCTs; emerging human data | Justice JN et al., 2019; Gonzales MM et al., 2023 |
| Metformin (off-label longevity use) | Investigational — Phase 3 TAME trial ongoing | Barzilai N et al., Cell Metabolism, 2016 |
What to Expect from a Longevity Protocol
4–8 Weeks
Most patients notice the first functional changes — improved energy, better sleep, enhanced mental clarity, early improvements in body composition — within four to eight weeks of initiating a protocol, particularly after hormone optimization or metabolic correction.
3 Months
Laboratory changes typically become measurable at the three-month assessment: reductions in hs-CRP, improvements in fasting insulin, hormonal normalization.
6–12 Months
More fundamental changes — shifts in biological age markers, measurable improvements in cellular repair capacity, reductions in senescence burden — take longer to manifest and are evaluated at the six-month and twelve-month assessments.
Longevity medicine is a long-term commitment, not a sprint. The payoff is not a dramatic short-term transformation but a sustained trajectory of healthier biological aging over years and decades.
Frequently Asked Questions
Scientific References
- Lopez-Otin C, et al. “Hallmarks of aging: An expanding universe.” Cell. 2023;186(2):243–278.
- Lee DH, et al. “Leisure-time physical activity and all-cause mortality.” JAMA Internal Medicine. 2022;182(12):1246–1254.
- Snyder PJ, et al. “Effects of testosterone treatment in older men.” NEJM. 2016;374(7):611–624.
- American Urological Association. “Testosterone Deficiency Guideline.” 2022.
- Yoshino M, et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity.” Science. 2021.
- Bhatt DL, et al. “Cardiovascular risk reduction with icosapentaenoic acid (REDUCE-IT).” NEJM. 2019;380(1):11–22.
- Justice JN, et al. “Senolytics in idiopathic pulmonary fibrosis.” EBioMedicine. 2019;40:554–563.
- Barzilai N, et al. “Metformin as a Tool to Target Aging.” Cell Metabolism. 2016;23(6):1060–1065.
Design Your Personalized Longevity Protocol
Schedule a consultation to begin your comprehensive biomarker assessment.